8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(D) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported):    June 3, 2009

Medizone International, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Nevada

(State of Other Jurisdiction of Incorporation)

002-93277-D

 87-0412648

(Commission File Number)

(IRS Employer Identification No.)

144 Buena Vista, P.O. Box 742, Stinson Beach, California

    94970

(Address of Principal Executive Offices)

(Zip Code)

(415) 868-0300

(Registrant’s Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Item 7.01

Regulation FD Disclosure.

On June 3, 2009, Medizone International, Inc. (“the Company”) issued a press release announcing a second series of laboratory trials of the Company’s AsepticSure^TM hospital sterilization technology.

A copy of the press release is furnished herewith as Exhibit 99 to this Current Report on Form 8-K and is incorporated herein by reference.  The Company will also post this document on its corporate website, www.medizoneint.com, under the "Press Releases" link.

In accordance with General Instruction B.2 of Form 8-K, the information in this section of this Report shall not be deemed filed for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing.

Item 9.01.  Financial Statements and Exhibits.

(d)

Exhibits.  

99

Press Release dated June 3, 2009

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Medizone International, Inc.

Date: June 3, 2009

By:  /s/ Edwin G. Marshall

     -----------------------------------------------

Edwin G. Marshall

Chairman of the Board and Chief Executive Officer

(Principal Executive Officer)

2

EX-99

Medizone International Inc. (MZEI.PK)

Medizone announces a second round of trials have begun.

San Francisco, California, June 3^rd, 2009. Medizone International is pleased to announce the commencement of a second series of laboratory trials of the Company’s AsepticSureÔ hospital sterilization technology, which is intended to build upon the success of its research to date.  Dr. Michael E. Shannon, Director of Medical Affairs for Medizone stated, "Our first round of trials using this technology produced results that exceeded our expectations in demonstrating significant bactericidal effects against C-difficile, E-coli, Pseudomonas aeruginous, MRSA and VRE, the main causative agents of hospital derived nosocomial infections.  With the introduction of several new technological developments into this next series of trials, we believe AsepticSureÔ will emerge dominant in the industry not only for the decontamina tion of hospital facilities but also for applications currently thought to be unassailable." 

Medizone anticipates completion of these new studies by early July, whereupon it intends to commence field trials in preparation for marketing later this calendar year.  To learn more about these global health concerns the AsepticSureÔ system addresses, please visit the company’s web site: www.medizoneint.com.  From the home page, go to AsepticSureÔ.  The presentation offered is a detailed analysis of the global health problems caused by hospital derived nosocomial infections.

Medizone International, Inc., is a research and development company engaged in developing its’ AsepticSureÔtechnology to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure.  If current trials continue to proceed successfully they will be followed by a hospital mock-up and then hospital beta testing of the production prototype.  Initial sales are targeted to commence in the 4^th quarter of this year.

This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.

Investor Relations 800-953-3350 / web site: www.medizoneint.com

E-mail: operations@medizoneint.com